Immunotherapy for small-cell lung cancer: rationale and clinical evidence

2017 ◽  
Vol 2 ◽  
pp. 3-3 ◽  
Author(s):  
Niki Karachaliou ◽  
Aaron E. Sosa ◽  
Rafael Rosell
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Evidence ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non–small cell lung cancer

2008 ◽  
Vol 135 (5) ◽  
pp. 1036-1041 ◽  
Author(s):  
Daniela Kandioler ◽  
Georgios Stamatis ◽  
Wilfried Eberhardt ◽  
Sonja Kappel ◽  
Sabine Zöchbauer-Müller ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Induction Chemotherapy ◽  
Cell Lung Cancer ◽  
Clinical Evidence ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 5956
Author(s):  
Noriaki Sunaga ◽  
Yosuke Miura ◽  
Norimitsu Kasahara ◽  
Reiko Sakurai
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Evidence ◽  
Treatment Strategies ◽  
Small Cell ◽  
Small Cell Lung ◽  
Kras Mutations ◽  
Nsclc Patients ◽  
Major Progress

Recent advances in molecular biology and the resultant identification of driver oncogenes have achieved major progress in precision medicine for non-small-cell lung cancer (NSCLC). v-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS) is the most common driver in NSCLC, and targeting KRAS is considerably important. The recent discovery of covalent KRAS G12C inhibitors offers hope for improving the prognosis of NSCLC patients, but the development of combination therapies corresponding to tumor characteristics is still required given the vast heterogeneity of KRAS-mutated NSCLC. In this review, we summarize the current understanding of KRAS mutations regarding the involvement of malignant transformation and describe the preclinical and clinical evidence for targeting KRAS-mutated NSCLC. We also discuss the mechanisms of resistance to KRAS G12C inhibitors and possible combination treatment strategies to overcome this drug resistance.

Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence

2017 ◽  
Vol 34 (6) ◽  
Author(s):  
Biagio Ricciuti ◽  
Marta Brambilla ◽  
Giulio Metro ◽  
Sara Baglivo ◽  
Roberta Matocci ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Evidence ◽  
Small Cell ◽  
Small Cell Lung

Ceritinib: an orphan drug for ALK positive non-small cell lung cancer with robust clinical evidence

2017 ◽  
Vol 5 (12) ◽  
pp. 991-997
Author(s):  
Christian Rolfo ◽  
David Arias ◽  
Jose Ferri Gandia ◽  
Paolo Manca ◽  
Edgardo Santos ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Orphan Drug ◽  
Cell Lung Cancer ◽  
Clinical Evidence ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Positive

Expression and clinical evidence of miR-494 and PTEN in non-small cell lung cancer

Tumor Biology ◽  
2015 ◽  
Vol 36 (9) ◽  
pp. 6965-6972 ◽  
Author(s):  
Juan Wang ◽  
Hongtao Chen ◽  
Yifeng Liao ◽  
Nan Chen ◽  
Tianze Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Evidence ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document